Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16352112 | 0.94 | ALOX5 (0.44) | ALOX5POLBSMN1; SMN2F2RL1AOC3 | |
| SCHEMBL16352148 | 0.88 | LTB4R (0.38) | ALDH1A1 | |
| SCHEMBL16352146 | 0.88 | MET (0.37) | SMN1; SMN2NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL16352140 | 0.86 | HCAR2 (0.38) | ALOX5ALDH1A1 | |
| SCHEMBL16363709 | 0.81 | ALOX5 (0.42) | ALOX5POLBSMN1; SMN2NPC1MAPT | |
| SCHEMBL16352101 | 0.81 | ALOX5 (0.42) | ALOX5POLBSMN1; SMN2NPC1MAPT | |
| SCHEMBL16352141 | 0.80 | LMNA (0.41) | ALOX5SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL16352110 | 0.79 | FFAR1 (0.39) | ALOX5MAPT | |
| SCHEMBL16352152 | 0.78 | MTNR1B (0.34) | POLB | |
| SCHEMBL9054554 | 0.77 | F2RL1 (0.53) | ALOX5POLBSMN1; SMN2F2RL1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593136-B2 | Compounds for inhibiting 1-deoxy-D-xylulose-5-phosphate reductoisomerase | THE GEORGE WASHINGTON UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20140378418-A1 | COMPOUNDS FOR INHIBITING 1-DEOXY-D-XYLULOSE-5-PHOSPHATE REDUCTOISOMERASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378418-A1 | COMPOUNDS FOR INHIBITING 1-DEOXY-D-XYLULOSE-5-PHOSPHATE REDUCTOISOMERASE | DCXR, G6PD, GRHPR | ALOX5 1559/4885POLB 1452/4885SMN1; SMN2 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.